Payload Information

General Information of This Payload

Payload ID	PAY0FNZBQ
Name	SC-DR003
Target(s)	Human Deoxyribonucleic acid (hDNA)	Target Info

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

SC-006 [Phase 1 (Terminated)]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	0.00%
Patients Enrolled	Patients with advanced metastatic or unresectable colorectal cancer.
Administration Dosage	SC-006-monotherapy, 2 to 12 ug/kg IV every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT03035279	Phase Status	Phase 1
Clinical Description	An open label phase 1 study of SC-006 as a single agent and in combination with ABBV-181 in subjects with advanced colorectal cancer.

References

Ref 1	Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023.